Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Virpax Pharmaceuticals, Inc. (VRPX : NSDQ)
 
 • Company Description   
Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Virpax Pharmaceuticals Inc. is based in WEST CHESTER, PA.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.29 Daily Weekly Monthly
20 Day Moving Average: 321,316 shares
Shares Outstanding: 11.72 (millions)
Market Capitalization: $15.11 (millions)
Beta: 4.55
52 Week High: $22.90
52 Week Low: $1.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -32.46% -23.94%
12 Week -37.07% -30.83%
Year To Date -62.39% -52.27%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1055 Westlakes Drive Suite 300
-
Berwyn,PA 19312
USA
ph: 610-727-4597
fax: -
betsy.brod@affinitygrowth.com http://www.virpaxpharma.com
 
 • General Corporate Information   
Officers
Anthony Mack - Chief Executive Officer and Director
Thani Jambulingam - Director and Chairman
Christopher Chipman - Chief Financial Officer
Gary Jacob - Director
Vanila M. Singh - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 928251107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 11.72
Most Recent Split Date: (:1)
Beta: 4.55
Market Capitalization: $15.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.46
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 26.67%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -49.78
12/31/21 - -50.21
09/30/21 - -63.63
ROA
03/31/22 - -45.94
12/31/21 - -44.88
09/30/21 - -50.59
Current Ratio
03/31/22 - 15.89
12/31/21 - 18.95
09/30/21 - 23.88
Quick Ratio
03/31/22 - -
12/31/21 - 18.95
09/30/21 - 23.88
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.78
12/31/21 - 3.20
09/30/21 - 3.54
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©